Connect with us


CBD Treatment Case: Alzheimer’s Disease



To understand the role that CBD can play in the treatment and therapy for those suffering from Alzheimer’s disease, it’s important to understand the facts about this terrible and life-changing condition.

Causality is still a mystery where Alzheimer’s disease is concerned. But, every day, scientists are making progress in our understanding of how the disease works, what preconditions may be red flags, and how individuals stricken with the disease may better cope with their lot in life.

Understanding Alzheimer’s Disease

Alzheimer’s disease is a form of dementia that leads to a progressive degeneration in overall cerebral cortex functioning.

Alzheimer’s results in a loss of functionality for neurons that have accumulated a buildup of what’s known as “plaque” in the brain. That leads to a progressive loss of functionality and, over time, a complete degeneration of neuronal tissue.

For those suffering from this condition, there is both a degeneration in functionality and a loss of brain matter, known as atrophy.

As you can imagine, given the brain’s central role in so many different facets of our experience of existence, there are enormous implications of the progression of this disease that impact our perception of ourselves as well as others’ perceptions of us through changes in our behavior.

Interestingly, we have seen some remarkable results from alternative therapies. For example, music therapy – a process characterized by the active participation of a patient in the creation of a new piece of music – has resulted in an almost instant remission of the behavioral facets of Alzheimer’s disease.

As noted above, one of the most important symptoms of the progression of Alzheimer’s disease is a buildup of beta amyloid plaque within the neurons themselves. This hinders the functionality of the neuron and also triggers an immune response from the body that eventually destroys the cell.

In many ways, Alzheimer’s is relatively similar to multiple sclerosis. However, where multiple sclerosis results in motor damage, Alzheimer’s results in cognitive damage.

Importantly, there is a large immune system component to the progression of Alzheimer’s that should suggest how CBD can play a role in therapy.

CBD and Alzheimer’s

As we have noted in numerous places, the endocannabinoid system is intimately involved in the functionality of the immune system. In fact, the endocannabinoid system is tied into many different maintenance systems that power human physiology.

In addition, Alzheimer’s disease is intimately tied into a balancing act by various interlinked systems in the body, including protective cells, metabolic byproducts, and proteins involved in brain functioning.

As the body ages, and as oxidative stress accumulates in various systems impacting brain functionality, the proteins central to these processes begin to fuse together after dislodging, eventually forming clumped segments of peptides that form the starting place for the buildup of beta amyloid plaque so characteristic in those suffering from Alzheimer’s disease.

CBD, which as we have noted is an important regulator of the immune system, is also a very important antioxidant. In other words, not only is CBD able to relax the aggressiveness of the immune system as it destroys neurons, but it also reduces the oxidative stress that dislodges the important proteins into peptide clumps that eventually result in the plaque that underlies Alzheimer’s disease.

Much research remains, but one thing is clear: CBD may form the central axis of a two-pronged attack that presents itself as a potentially important tool in the battle to defend quality of life for those suffering from this terrible disease.

Continue Reading


WeedMD Inc (OTCMKTS:WDDMF) Rolls Out Its Color Cannabis Brand For Adults



WeedMD Inc (OTCMKTS:WDDMF) has announced the launch of its latest brand called Color Cannabis as a premium brand that targets adult users that want high-grade cannabis products.

The new Color Cannabis premium brand features numerous strains of cannabis that are presented in multiple formats. However, they are also developed such that they have a high level of quality as per the expectations of the target consumers. WeedMD’s new brand will only be available to a few distributors and retailers in Canada.

WeedMD plans to have the Color Cannabis-branded products in select stores as well as online availability by Mid-June. The company created the brand with a strategic aim at the diverse preference and tastes of the modern-day cannabis consumer.

“We worked with globally-renowned agency Sid Lee to launch Color – our first adult-use brand,” stated Brett Moon, the Senior Vice President of sales and marketing at WeedMD.

The Color Cannabis brand to mainly focus on a premium user experience

Mr. Moon also noted that Color Cannabis is designed to inspire customers to embrace life and their cannabis experience in personal and unique ways. Aside from being available in the form of dried premium flower, the new WeedMD brand also hosts new product formats over the next few months. Some of those products include gel capsules, oils and pre-rolls and they will be made available with the creation of more consumption formats.

WeedMD CEO Keith Merker stated that Color Cannabis’ goal is to grasp the progressive character, individuality, and imagination of cannabis users. The CEO noted that the goal of the brand is not to tell clients what they will feel but rather to experience the products for themselves. Merker also noted that the Color Cannabis launch represents a key milestone for the company.

WeedMD expects to juggle between the new adult cannabis brand and its medical cannabis pursuits. The company expects to produce about 150,000 kilograms through its 5.2 million square feet production capacity by 2020. The firm also expects to have enough room to handle production for medical cannabis, as well as recreational adult use. It plans to achieve this through its indoor and outdoor growth facilities.

Continue Reading


HempAmericana Inc. (OTCMKTS:HMPQ) CEO Issues Explains The Company’s Expansion



HempAmericana Inc. (OTCMKTS:HMPQ) CEO has issued a letter to shareholders addressing the expansion of the company following string orders.

HempAmericana has begun bottling of full-spectrum CBD distillate

In the letter to shareholders, the CEO indicated that the company has begun establishing growth momentum in its CBD oil production as well as the distribution business. The CEO stated that the company has started bottling of 500 mg as well as 1000 mg full spectrum CBD distillate in its ultramodern CBD production and extraction facility in Augusta Maine.

He added that the company’s initial production is expected to be around 2,000 bottles per day which will be increased gradually to around 8,000 bottles a day to meet demand. Currently, the company has more than 50,000 full spectrum distillate bottles that are ready to be shipped with tens of thousands expected to follow.

HempAmericana is equally bottling a 250 mg potency that is suitable for the CBD-for-pets market. On the high end, the CEO indicated that the company is bottling 2500 mg and 5000 mg but he asserted that they have the potential of replicating any formula.

The CEO further went on to explain that production will be distributed under the company’s proprietary brand “Weed Got Oil.” He added that the company is also pursuing an opportunity in the white label market for the quality full-spectrum distillate CBD Oil. Currently, there are over 400 brands in the CBD market with the majority turning to high capacity producers such as HempAmericana to build product inventory.

Relationship with Eagle Hemp

The company recently announced a relationship with Florida based Eagle Hemp for an initial purchase order as well as the establishment of connections for more orders in the future. The company anticipates strong demand that includes compensation for more production of CBD oil as well as its bottling technology. The first order will bring the company significant revenue input at no associated costs to labeling, bottling, and shipping.

The company’s production facility and lab are currently operating well with two bottling machines in operation. The CEO said that once they distill the interest into purchase orders they will communicate to shareholders.

Continue Reading


Medmen Enterprises Inc. (OTCMKTS:MMNFF) Expands Its Footprint In California With Acquisition Of One Love



MedMen Enterprises Inc. (OTCMKTS:MMNFF) has announced the signing of a definitive agreement for the acquisition of 100% interest in MattnJeremy, Inc. One Love Beach Club.

Acquisition of One Love

The acquisition enhances the company’s California footprint by adding a premier location that is positioned strategically between its LAX and Santa Ana locations. The One Love Beach Club is currently on a run-rate of around $6 million in gross revenue and has an unaudited EBITDA margin of about 29%.

MedMen CEO Adam Bierman stated that they were delighted to have Long Beach on bard as part of the MedMen family as the company continues its growth in the world’s leading cannabis market.

One love was founded back in 2009 and it is located in Long Beach at 2767 E Broadway between Belmont Shore and Downtown some blocks from the beach. Long Beach is located 20 miles from Los Angeles and it is the third largest city in Southern California behind San Diego and Los Angeles with a population of almost half a million.

The city is a prime location that offers attractions, oceanfront hotels, events, recreation activities, shopping, nightly entertainment, restaurants as well as art and culture. According to the Long Beach Convention & Visitors Bureau in 2018 there were approximately 7.9 million visitors who visited the city to attend various events and attractions.

The One Love owner and operator Abrams Family indicated that it had been exciting to have served the Long Beach community for the last ten years adding that they were looking forward to MedMen to continue offering the community with premium cannabis.

Details of the transaction

According to the details of the transaction MedMen is expected to pay around $13 million of which $1 million will be in cash at closing of the deal and $2 million in deferred cash. The rest of the $10 million shall be fulfilled in Class B Subordinate Voting shares. Completion of the transactions depends on regulatory approval by state and local authorities as well as other routine closing conditions. The deal is expected to be closed within 45 days.

Continue Reading

Trending Stories